Saint Louis University Menu Search

14-011 - Suppression of bone loss by introducing FoxP3+CD8 T-cells


Rajeev Aurora and Zachary Buchwald


Provided are systems and methods for inhibiting bone loss in a patient by administering a periodic low dose of RANK agonist to generate in vivo FoxP3+ CD8 T-cells (TcREG). TREG prevent the activation of self-reactive T-cells and suppress inflammation by a number of mechanisms, including inhibiting secretion of IL-10. Thus, the ability of TcREG to limit bone resorption and inflammation could be used to treat conditions like osteoporosis and rheumatoid arthritis.

Intellectual Property Status

  • U.S. patent pending